Founded in 2019, Haorui Genomics focuses on the R&D and application of long-read sequencing technologies, as well as the development of clinical molecular diagnostic products and big data platforms. Backed by a comprehensive suite of mainstream long-read sequencing equipment and a professional team with years of industry expertise, we have built an end-to-end product and technical service system centered on long-read sequencing, continuously driving innovative sequencing technologies to deliver greater clinical value.
Our research services cater to universities and research institutions nationwide, offering cutting-edge multi-omics sequencing solutions. Core services include whole-genome sequencing, pan-genome research, T2T and haplotype genome assembly, full-length transcriptome sequencing, genome resequencing, Hi-C analysis, single-cell transcriptome sequencing, and spatial transcriptome analysis.
We have established in-depth collaborations with hundreds of research institutes, successfully conducting sequencing studies on over 100 species across aquatic, terrestrial, and aerial categories. We provide efficient, precise technical support for fundamental and applied research in the life sciences.
We specialize in innovative clinical molecular diagnostics, delivering tailored solutions for transplantation matching, precision transfusion, genetic disease screening, and pharmacogenomic analysis.
We have built two core product portfolios:
AltruTypeTM: A pioneering locally deployable long-read HLA genotyping solution, covering 14 genes for clinical HLA testing.
HemoSureTM: A full-spectrum blood group genotyping product, covering 22 red blood cell blood group systems and all typing loci of the platelet HPA system, forming a precise line of defense for clinical transfusion safety.
Additionally, we have developed targeted product lines for genetic disease testing and pharmacogenomics, tailored to diverse clinical scenarios. We maintain in-depth cooperation with hundreds of blood banks and hospitals at home and abroad, helping to solve complex clinical diagnostic challenges.
Through continuous technological innovation and industry contributions, Haorui Genomics has been certified as a Shaanxi Provincial High-Tech Enterprise, Shaanxi Specialized, Refined, Characteristic and Innovative Enterprise, and Xi’an Gazelle Enterprise.
We are a pioneer in filing domestic and international patents for long-read sequencing-based genetic testing, as well as CE-IVD certifications. We hold more than ten software copyrights and authorized patents. Our research and medical teams have published over 68 high-impact papers in international authoritative journals such as Cell, Nature Communications,Nature Genetics, Blood Advances, and Clinical Chemistry.
Our laboratory has officially obtained ISO9001 Quality Management System, ISO14001 Environmental Management System, and ISO45001 Occupational Health and Safety Management System certifications. We adhere to high-standard compliant operations to ensure the quality of our products and services.
WeChat QR Code